Eleven years of experience with bisphosphonate plus alfacalcidol treatment in a man with osteogenesis imperfecta type I

References

• KingJDBobechkoWPOsteogenesis imperfecta. An orthopaedic description and surgical reviewJ Bone Joint Surg Br1971537289
   Google Scholar
• AlbrightJAGruntJAStudies of patients with osteogenesis imperfectaBone Joint Surg Am19715314151425
   PubMed Web of Science ®Google Scholar
• BaronRGertnerJMLangRIncreased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tardaPediatr Res1983172042076835724
   PubMed Web of Science ®Google Scholar
• RileyFCJowseyJBrownDMOsteogenesis imperfecta: morphologic and biochemical studies of connective tissuePediatr Res197377577684744658
   PubMed Web of Science ®Google Scholar
• RauchFTraversRParfittAMStatic and dynamic bone histomorphometry in children with osteogenesis imperfectaBone20002658158910831929
   PubMed Web of Science ®Google Scholar
• BrennerREVetterUBollenAMBone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfectaJ Bone Miner Res199499939977942168
   PubMed Web of Science ®Google Scholar
• AstromESoderhallSBeneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfectaArch Dis Child20028635636411970931
   PubMed Web of Science ®Google Scholar
• GlorieuxFHBishopNJPlotkinHCyclic administration of pamidronate in children with severe osteogenesis imperfectaN Engl J Med19983399479529753709
   PubMed Web of Science ®Google Scholar
• GlorieuxFHBisphosphonate therapy for severe osteogenesis imperfectaJ Pediatr Endocrinol Metab20001398999211086652
   PubMed Web of Science ®Google Scholar
• GonzalezEPaviaCRosJEfficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfectaJ Pediatr Endocrinol Metab20011452953311393574
   PubMed Web of Science ®Google Scholar
• LeeYSLowSLLimLACyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfectaEur J Pediatr200116064164411760017
   PubMed Web of Science ®Google Scholar
• PlotkinHRauchFBishopNJPamidronate treatment of severe osteogenesis imperfecta in children under 3 years of ageJ Clin Endocrinol Metab2000851846185010843163
   PubMed Web of Science ®Google Scholar
• WardLMRauchFWhyteMPAlendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled studyJ Clin Endocrinol Metab20119635536421106710
   PubMed Web of Science ®Google Scholar
• IwamotoJMatsuKTakedaTEffects of treatment with etidronate and alfacalcidol for osteogenesis imperfecta type I: a case reportJ Orthop Sci2003824324712665966
   PubMedGoogle Scholar
• IwamotoJTakedaTSatoYEffect of treatment with alendronate in osteogenesis imperfecta type I: a case reportKeio J Med20045325125515647630
   PubMedGoogle Scholar
• IwamotoJTakedaTIchimuraSEffects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosisJ Orthop Sci2003853253712898306
   PubMedGoogle Scholar
• OrimoHNakamuraTFukunagaMEffects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT)-02Curr Med Res Opin2011271273128421554143
   PubMed Web of Science ®Google Scholar
• RingeJDFarahmandPSchachtESuperiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial)Rheumatol Int20072742543417216477
   PubMed Web of Science ®Google Scholar
• SillenceDOOsteogenesis imperfecta nosology and geneticsAnn NY Acad Sci19885431153063156
   PubMedGoogle Scholar
• OrimoH[Japanese guideline for prevention and treatment of osteoporosis]Life Science2011 Japanese
   Google Scholar
• OrimoHSugiokaYFukunagaMDiagnostic criteria of primary osteoporosisJ Bone Miner Metab199816139150
   Web of Science ®Google Scholar
• OrimoHHayashiYFukunagaMDiagnostic criteria for primary osteoporosis: year 2000 revisionJ Bone Miner Metab20011933133711685647
   PubMed Web of Science ®Google Scholar
• NishizawaYNakamuraTOhtaHCommittee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis Japan Osteoporosis Society. Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004)J Bone Miner Metab2005239710415750686
   PubMed Web of Science ®Google Scholar
• KushidaKShirakiMNakamuraTThe efficacy of alendronate in reducing the risk of vertebral fracture in Japanese patients with osteoporosis: A randomized, double-blind, active-controlled, double-dummy trialCurr Ther Res Clin Exp200263606620
   Web of Science ®Google Scholar
• KushidaKShirakiMNakamuraTAlendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up studyJ Bone Miner Metab20042246246815316867
   PubMed Web of Science ®Google Scholar
• ShirakiMKushidaKFukunagaMA double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosisOsteoporos Int19991018319210525709
   PubMed Web of Science ®Google Scholar
• UchidaSTaniguchiTShimizuTTherapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized studyJ Bone Miner Metab20052338238816133688
   PubMed Web of Science ®Google Scholar
• CortetBBéra-LouvilleAGauthierPComparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. Effect of adding hormone replacement therapyJoint Bone Spine20016841041511707007
   PubMed Web of Science ®Google Scholar
• KhoslaSBurrDCauleyJBisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res2007221479149117663640
   PubMed Web of Science ®Google Scholar
• ShaneEBurrDEbelingPRAtypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral ResearchJ Bone Miner Res2010252267229420842676
   PubMed Web of Science ®Google Scholar
• AndersonFHFrancisRMBishopJCEffect of intermittent cyclical disodium etidronate therapy on bone mineral density in men with vertebral fracturesAge Ageing1997263593659351480
   PubMed Web of Science ®Google Scholar
• IwamotoJTakedaTSatoYComparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosisClin Rheumatol20072616116716565894
   PubMed Web of Science ®Google Scholar
• IwamotoJTakedaTIchimuraSIncreased bone resorption with decreased activity and increased recruitment of osteoblasts in osteogenesis imperfecta type IJ Bone Miner Metab20022017417911984701
   PubMed Web of Science ®Google Scholar
• AgarwalaSSuleAPaiBUAlendronate in the treatment of avascular necrosis of the hipRheumatology (Oxford)20024134634711934975
   PubMed Web of Science ®Google Scholar
• GangjiVAppelboomTAnalgesic effect of intravenous pamidronate on chronic back pain due to osteoporotic vertebral fracturesClin Rheumatol19991826626711206358
   PubMed Web of Science ®Google Scholar
• GloverDLiptonAKellerAIntravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A doseseeking studyCancer199474294929557525038
   PubMed Web of Science ®Google Scholar
• HortobagyiGNTheriaultRLPorterLEfficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastasesN Engl J Med1996335178517918965890
   PubMed Web of Science ®Google Scholar
• SirisESChinesAAAltmanRDRisedronate in the treatment of Paget’s disease of bone: an open label, multicenter studyJ Bone Miner Res199813103210389626635
   PubMed Web of Science ®Google Scholar
• BrownMFHukkanenMVMcCarthyIDSensory and sympathetic innervation of the vertebral endplate in patients with degenerative disc diseaseJ Bone Joint Surg Br1997791471539020464
   PubMedGoogle Scholar
• HartmanJMBergerABakerKPOWER (Premenopausal, Osteoporosis, Women, Alendronate, Depression) Study Group. Quality of life and pain in premenopausal women with major depressive disorder: the POWER studyHealth Qual Life Outcomes20064216420706
   PubMed Web of Science ®Google Scholar
• OhtoriSInoueGKoshiTSensory innervation of lumbar vertebral bodies in ratsSpine (Phila Pa 1976)2007321498150217572618
   PubMed Web of Science ®Google Scholar
• OhtoriSInoueGKoshiTCharacteristics of sensory dorsal root ganglia neurons innervating the lumbar vertebral body in ratsJ Pain2007848348817382597
   PubMed Web of Science ®Google Scholar
• BianchiMFranchiSFerrarioPEffects of the bisphosphonate ibandronate on hyperalgesia, substance P, and cytokine levels in a rat model of persistent inflammatory painEur J Pain20081228429217664076
   PubMed Web of Science ®Google Scholar
• OritaSOhtoriSKoshiTThe effects of risedronate and exercise on osteoporotic lumbar rat vertebrae and their sensory innervationSpine2010351974198220959778
   PubMed Web of Science ®Google Scholar
• SeemanETo stop or not to stop, that is the questionOsteoporos Int20092018719519096746
   PubMed Web of Science ®Google Scholar
• CompstomJEBilezikianJPBisphosphonate therapy for osteoporosis: the long and short of itJ Bone Miner Res20122724024222271395
   PubMed Web of Science ®Google Scholar
• WhitakerMGuoJKehoeTBisphosphonates for osteoporosis – where do we go from here?N Engl J Med20123662048205122571168
   PubMed Web of Science ®Google Scholar
• BlackDMBauerDCSchwartzAVContinuing bisphosphonate treatment for osteoporosis – for whom and for how long?N Engl J Med20123662051250322571169
   PubMed Web of Science ®Google Scholar